rivaroxaban / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 97 Diseases   239 Trials   239 Trials   14341 News 


«12...89101112131415161718...166167»
  • ||||||||||  rivaroxaban / Generic mfg.
    Anesthetic Management of Patient with Conn's Syndrome Undergoing Urgent Orthopedic Surgery (Exhibit Hall) -  Aug 23, 2023 - Abstract #ASA2023ASA_4076;    
    This case highlights the anesthetic management of long standing uncontrolled hypertension and its deleterious cardiac effects, renal disease, and hypokalemia secondary to Conn's Syndrome. In particular, hemodynamic management, avoidance of hyperventilation, and potential for prolongation of neuromuscular blocking agents.
  • ||||||||||  rivaroxaban / Generic mfg.
    Massive Bleeding Tongue Hematoma In An Alcoholic, Requiring Advanced Airway And Critical Care (Exhibit Hall) -  Aug 23, 2023 - Abstract #ASA2023ASA_3815;    
    Xarelto reversed with PCC and the patient was taken emergently to the OR for Fiberoptic nasal intubation, drain placement and then admitted to the ICU. Tongue swelling decreased and he was extubated 9 days after initial presentation after which he was transferred out of the ICU and eventually home with multidisciplinary follow up.
  • ||||||||||  rivaroxaban / Generic mfg.
    Left Adrenalectomy In Patient With Common Atrium And Biventricular Failure (Exhibit Hall) -  Aug 23, 2023 - Abstract #ASA2023ASA_3775;    
    43 year-old male with NICM (EF 30%) due to congenital ASD left-to-right shunt (Qp/Qs 3.4), pHTN and congestive hepatopathy, AFib on Xarelto, T2DM, HTN and diagnosed pheochromocytoma underwent left adrenalectomy with ECMO on standby...Our team optimized the patient preoperatively and discussed intraoperative goals, such as maintaining SVR and PVR in a laparoscopic case. The patient ultimately underwent a successful left adrenalectomy without intraoperative complications or implementation of ECMO and was discharged home 3 days postoperatively.
  • ||||||||||  Review, Journal, Surgery:  Venous Thromboembolism Prophylaxis in Major Orthopedic Surgeries and Factor XIa Inhibitors. (Pubmed Central) -  Aug 22, 2023   
    For most patients undergoing knee or hip arthroplasty, the initial agents recommended for the early perioperative period are LMWHs (enoxaparin or dalteparin) or direct oral anticoagulants (rivaroxaban or apixaban)...However, emerging factor XI(a) inhibitors, as revealed by a recent meta-analysis, have shown a substantial decrease in the occurrence of VTE and bleeding events among patients undergoing major orthopedic surgery. This discovery poses a challenge to the existing paradigm of anticoagulant therapy in this specific patient population and indicates that factor XI(a) inhibitors hold great promise as a potential strategy to be taken into serious consideration.
  • ||||||||||  Savaysa (edoxaban) / Daiichi Sankyo
    Enrollment change, Trial completion date, Trial primary completion date:  PRESTIGE-AF: PREvention of STroke in Intracerebral haemorrhaGE Survivors With Atrial Fibrillation (clinicaltrials.gov) -  Aug 21, 2023   
    P3,  N=350, Recruiting, 
    The prescribing pattern can be improved by reducing the number of drugs prescribed. N=654 --> 350 | Trial completion date: Nov 2022 --> May 2024 | Trial primary completion date: May 2022 --> May 2024
  • ||||||||||  rivaroxaban / Generic mfg.
    Journal:  Rivaroxaban treatment for asymptomatic venous thromboembolism: insights from the J'xactly study. (Pubmed Central) -  Aug 20, 2023   
    N=654 --> 350 | Trial completion date: Nov 2022 --> May 2024 | Trial primary completion date: May 2022 --> May 2024 The real-world composite adverse event rate for treatment with rivaroxaban, as physician-adjusted for dose and duration, was similar for asymptomatic and symptomatic patients regardless of the presence of PE or DVT, suggesting a favorable safety profile for potential rivaroxaban treatment for asymptomatic VTE.
  • ||||||||||  Savaysa (edoxaban) / Daiichi Sankyo
    Review, Journal:  Prescription of DOACs in Patients with Atrial Fibrillation at Different Stages of Renal Insufficiency. (Pubmed Central) -  Aug 18, 2023   
    This review article provides an overview of current knowledge on the selection and dose of DOACs including apixaban, dabigatran, edoxaban and rivaroxaban in AF patients at different stages of renal insufficiency, with a special focus on elderly patients with comorbidities and receiving multiple medications. The groups discussed in this review include patients with varying levels of CrCl including hyperfiltration or CrCl?>?90
  • ||||||||||  Savaysa (edoxaban) / Daiichi Sankyo
    Review, Journal:  Studies on Atrial Fibrillation and Venous Thromboembolism in the Past 20?Years: A Bibliometric Analysis Via CiteSpace and VOSviewer. (Pubmed Central) -  Aug 16, 2023   
    Studies during 2017 to 2022 focused on apixaban, direct oral anticoagulant, rivaroxaban, dabigatran, hemorrhage, edoxaban, medicine efficacy and safety, risk factors, clinical management, and vitamin K antagonists...On the whole, most studies of AF and VTE focus on pathogenesis and therapeutic drugs. The causal relationship between AF and VTE, the effectiveness and safety of novel oral anticoagulants in the treatments, the anticoagulant regimen of AF and VTE co-disease, and the treatment regimen for vulnerable populations such as the elderly or obese people were the focus of current research and will continue to be the central point of future research.
  • ||||||||||  rivaroxaban / Generic mfg.
    Journal:  Buddi-Chiari syndrome associated with hypereosinophilic syndrome: A case report. (Pubmed Central) -  Aug 15, 2023   
    The patient, in this case, was finally diagnosed with BCS combined with hypereosinophilic syndrome, and to our knowledge, such case reports are rare. Our case report suggest an association between BCS and hypereosinophilic syndrome, but relevant studies are minimal, we hope to conduct larger and higher quality studies on these patients in the future, to provide new directions and basis for the etiology and pathogenesis of these diseases, as well as provide new targets and ideas for clinical treatment.
  • ||||||||||  Savaysa (edoxaban) / Daiichi Sankyo
    Journal, Adverse events, Adverse drug reaction:  Identification of risk factors for adverse drug reactions in a pharmacovigilance database. (Pubmed Central) -  Aug 15, 2023   
    We demonstrated that data mining within a pharmacovigilance database identifies known risk factors for DOAC bleeding, and potential risk factors such as dementia and atrial fibrillation. We propose that the method could be used in pharmacovigilance for identification of potential ADR risk factors that merit further evaluation.
  • ||||||||||  rivaroxaban / Generic mfg.
    Journal:  Rivaroxaban attenuates neutrophil maturation in the bone marrow niche. (Pubmed Central) -  Aug 14, 2023   
    In translation, ST-elevation MI patients treated with rivaroxaban also exhibited reduced circulating leukocyte numbers. In conclusion, we demonstrate that rivaroxaban attenuates neutrophil maturation in the BM, which may offer a therapeutic option to limit overshooting of the immune response after I/R.
  • ||||||||||  rivaroxaban / Generic mfg., dabigatran etexilate / Generic mfg., apixaban / Generic mfg.
    Journal:  Therapeutic Drug Monitoring of Direct Oral Anticoagulants in Patients with Extremely Low and High Body Weight-Pilot Study. (Pubmed Central) -  Aug 12, 2023   
    Among subjects taking apixaban, rivaroxaban, and dabigatran, the smallest representation of patients who achieved therapeutic concentrations were those treated with dabigatran. The population of people with abnormal body weight is a potential risk group of patients, in which some of them do not reach the therapeutic range of DOACs.
  • ||||||||||  rivaroxaban / Generic mfg., apixaban / Generic mfg.
    Reimbursement, US reimbursement, Journal, Medicare:  Unintended Consequences of Increased Out-of-Pocket Costs During Medicare Coverage Gap on Anticoagulant Discontinuation and Stroke. (Pubmed Central) -  Aug 12, 2023   
    The population of people with abnormal body weight is a potential risk group of patients, in which some of them do not reach the therapeutic range of DOACs. Increased OOP costs during Medicare coverage gap were associated with higher risk of DOAC discontinuation, which in turn was associated with higher risk of stroke and SE among beneficiaries with NVAF.
  • ||||||||||  rivaroxaban / Generic mfg., warfarin / Generic mfg., apixaban / Generic mfg.
    Reimbursement, US reimbursement, Journal:  Reimbursement and use of oral anticoagulants during 2014-2022 - A register-based study. (Pubmed Central) -  Aug 4, 2023   
    The number of warfarin users declined since 2015 from over 181,000 to around 59,000 users in 2022, DOACs exceeding warfarin in the number of users in 2019...Rivaroxaban was the most widely used DOAC during 2014-2018, and apixaban during 2019-2022...During the 2010s, the treatment guidelines for AF were more cautious in recommending DOACs than the European guidelines. The use of DOACs increased as their reimbursement became less restrictive.